XBiotech Inc. (NASDAQ:XBIT) gapped up before the market opened on Friday . The stock had previously closed at $15.30, but opened at $15.32. XBiotech shares last traded at $15.69, with a volume of 38,534 shares trading hands.

A number of equities research analysts have issued reports on the stock. Noble Financial restated a “buy” rating and set a $30.00 price target (up from $24.00) on shares of XBiotech in a report on Tuesday, June 28th. Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, May 24th.

The firm’s 50 day moving average is $16.20 and its 200-day moving average is $12.67. The company’s market capitalization is $498.84 million.

In related news, Director W Thorpe Mckenzie acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were acquired at an average cost of $13.96 per share, with a total value of $279,200.00. Following the transaction, the director now owns 3,898,600 shares of the company’s stock, valued at approximately $54,424,456. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.